Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

The translocator protein.

Scarf AM, Kassiou M.

J Nucl Med. 2011 May;52(5):677-80. doi: 10.2967/jnumed.110.086629. Epub 2011 Apr 15. Review.

2.

Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair.

Chen MK, Guilarte TR.

Pharmacol Ther. 2008 Apr;118(1):1-17. doi: 10.1016/j.pharmthera.2007.12.004. Epub 2008 Feb 9. Review.

3.

Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography.

Dollé F, Luus C, Reynolds A, Kassiou M.

Curr Med Chem. 2009;16(22):2899-923. Review.

PMID:
19689272
4.

Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.

Dupont AC, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N.

Int J Mol Sci. 2017 Apr 7;18(4). pii: E785. doi: 10.3390/ijms18040785. Review.

5.

Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands.

Owen DR, Matthews PM.

Int Rev Neurobiol. 2011;101:19-39. doi: 10.1016/B978-0-12-387718-5.00002-X. Review.

PMID:
22050847
6.

The methodology of TSPO imaging with positron emission tomography.

Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, Veronese M.

Biochem Soc Trans. 2015 Aug;43(4):586-92. doi: 10.1042/BST20150058. Epub 2015 Aug 3. Review.

7.

Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls.

Scott G, Mahmud M, Owen DR, Johnson MR.

Seizure. 2017 Jan;44:42-47. doi: 10.1016/j.seizure.2016.10.023. Epub 2016 Nov 13. Review.

PMID:
27884611
8.

Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection.

Da Pozzo E, Giacomelli C, Barresi E, Costa B, Taliani S, Passetti Fda S, Martini C.

Biochem Soc Trans. 2015 Aug;43(4):559-65. doi: 10.1042/BST20150028. Epub 2015 Aug 3. Review.

PMID:
26551693
9.

Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?

Vivash L, O'Brien TJ.

J Nucl Med. 2016 Feb;57(2):165-8. doi: 10.2967/jnumed.114.141713. Epub 2015 Dec 23. Review.

10.

Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands.

Taliani S, Pugliesi I, Da Settimo F.

Curr Top Med Chem. 2011;11(7):860-86. Review.

PMID:
21291396
11.

The translocator protein as a drug target in Alzheimer's disease.

Chua SW, Kassiou M, Ittner LM.

Expert Rev Neurother. 2014 Apr;14(4):439-48. doi: 10.1586/14737175.2014.896201. Review.

PMID:
24625007
12.

Computational studies on translocator protein (TSPO) and its ligands.

Ortore G, Tuccinardi T, Martinelli A.

Curr Top Med Chem. 2012;12(4):352-9. Review.

PMID:
22204485
13.

Translocator protein: pharmacology and steroidogenesis.

Midzak A, Zirkin B, Papadopoulos V.

Biochem Soc Trans. 2015 Aug;43(4):572-8. doi: 10.1042/BST20150061. Epub 2015 Aug 3. Review.

PMID:
26551695
14.

Targeting of the translocator protein 18 kDa (TSPO): a valuable approach for nuclear and optical imaging of activated microglia.

Trapani A, Palazzo C, de Candia M, Lasorsa FM, Trapani G.

Bioconjug Chem. 2013 Sep 18;24(9):1415-28. doi: 10.1021/bc300666f. Epub 2013 Jul 23. Review.

PMID:
23837837
15.

The 18‚ÄČkDa translocator protein, microglia and neuroinflammation.

Liu GJ, Middleton RJ, Hatty CR, Kam WW, Chan R, Pham T, Harrison-Brown M, Dodson E, Veale K, Banati RB.

Brain Pathol. 2014 Nov;24(6):631-53. doi: 10.1111/bpa.12196. Review.

PMID:
25345894
16.

Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M.

Nat Rev Drug Discov. 2010 Dec;9(12):971-88. doi: 10.1038/nrd3295. Review.

PMID:
21119734
17.

TSPO is a REDOX regulator of cell mitophagy.

Gatliff J, Campanella M.

Biochem Soc Trans. 2015 Aug;43(4):543-52. doi: 10.1042/BST20150037. Epub 2015 Aug 3. Review.

PMID:
26551691
18.

Translocator protein as a promising target for novel anxiolytics.

Costa B, Da Pozzo E, Martini C.

Curr Top Med Chem. 2012;12(4):270-85. Review.

PMID:
22204481
19.

Tetrapyrroles as Endogenous TSPO Ligands in Eukaryotes and Prokaryotes: Comparisons with Synthetic Ligands.

Veenman L, Vainshtein A, Yasin N, Azrad M, Gavish M.

Int J Mol Sci. 2016 Jun 4;17(6). pii: E880. doi: 10.3390/ijms17060880. Review.

20.

Supplemental Content

Support Center